- Home
- SENS vs VTYX Comparison
SENS vs VTYX Comparison
Compare SENS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENS
- VTYX
- Stock Information
- Founded
- SENS 1996
- VTYX 2018
- Country
- SENS United States
- VTYX United States
- Employees
- SENS N/A
- VTYX N/A
- Industry
- SENS Industrial Machinery/Components
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SENS Industrials
- VTYX Health Care
- Exchange
- SENS Nasdaq
- VTYX Nasdaq
- Market Cap
- SENS 179.7M
- VTYX 154.9M
- IPO Year
- SENS N/A
- VTYX 2021
- Fundamental
- Price
- SENS $0.85
- VTYX $2.02
- Analyst Decision
- SENS Strong Buy
- VTYX Buy
- Analyst Count
- SENS 1
- VTYX 4
- Target Price
- SENS $2.00
- VTYX $11.33
- AVG Volume (30 Days)
- SENS 18.7M
- VTYX 2.0M
- Earning Date
- SENS 02-27-2025
- VTYX 02-25-2025
- Dividend Yield
- SENS N/A
- VTYX N/A
- EPS Growth
- SENS N/A
- VTYX N/A
- EPS
- SENS N/A
- VTYX N/A
- Revenue
- SENS $22,205,000.00
- VTYX N/A
- Revenue This Year
- SENS $0.12
- VTYX N/A
- Revenue Next Year
- SENS $61.22
- VTYX N/A
- P/E Ratio
- SENS N/A
- VTYX N/A
- Revenue Growth
- SENS 11.41
- VTYX N/A
- 52 Week Low
- SENS $0.25
- VTYX $1.67
- 52 Week High
- SENS $0.93
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- SENS 71.68
- VTYX 43.40
- Support Level
- SENS $0.67
- VTYX $1.90
- Resistance Level
- SENS $0.83
- VTYX $2.61
- Average True Range (ATR)
- SENS 0.11
- VTYX 0.18
- MACD
- SENS 0.03
- VTYX -0.04
- Stochastic Oscillator
- SENS 83.71
- VTYX 24.52
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.